You have matched to 2 trials

Guest Profile:  No profile selected

Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

Imaging and <span class="highlight">Tumor</span> Mark Tests to Monitor Metastatic HR Positive, HER2 Negative Breast Cancer

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum <span class="highlight">Tumor</span> Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer (SWOG-S1703)

Purpose: To study if <span class="highlight">blood</span> tests that look for <span class="highlight">tumor</span> <span class="highlight">markers</span> are as good as or better than imaging with PET and/or CT scans (the current standard of care) to determine if a <span class="highlight">tumor</span> is growing.

Who is this for?: People with metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to have first line treatment for metastatic disease or have started treatment within the past month, and have at least one elevated <span class="highlight">tumor</span> marker. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Imaging (CT and/or PET scans), at least every 3 months, ongoing</li> <li class="seamTextUnorderedListItem"><span class="highlight">Tumor</span> Marker Test, if ordered by your doctor</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"><span class="highlight">Tumor</span> Marker Tests, every 1 to 2 months, ongoing</li> <li class="seamTextUnorderedListItem">Imaging (CT and/or PET scans), only if need is shown by a <span class="highlight">Tumor</span> Marker Test</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"><span class="highlight">Blood</span> draws</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This imaging trial will compare using <span class="highlight">blood</span> tests to PET/CT scans for monitoring <span class="highlight">tumor</span> growth. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">tumor</span> <span class="highlight">markers</span> that will be tested for in this study are CA 15-3, CA27.29, and CEA.</li> <li class="seamTextUnorderedListItem">The imaging tests will be those ordered by your doctor.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03723928' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/blood_marker' target='_blank'>Breastcancer.org: Blood Marker Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/about-us/collaborations/top-five-list-oncology/choosing-wisely®-top-five-cancer-related-tests-procedures-and-treatments-many-patients-do-not-need/topic-4-follow-tumor-marker-tests-and-imaging-tests-people-treated-breast-cancer' target='_blank'>ASCO Cancer.net: Follow-up Tumor Marker Tests and Imaging Tests for People Treated for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet' target='_blank'>NCI: Tumor Markers</a> </li><li class='seamTextUnorderedListItem'><a href='https://ozarkscancerresearch.org/wp-content/uploads/2019/04/SWOG-S1703.pdf' target='_blank'>Cancer Research for the Ozarks: Trial Information Page</a> </li></ul>
1

Imaging and <span class="highlight">Tumor</span> Mark Tests to Monitor Metastatic HR Positive, HER2 Negative Breast Cancer

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum <span class="highlight">Tumor</span> Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer (SWOG-S1703)
Icon

Nearest Location:
8 miles
Epic Care Partners in Cancer Care
Emeryville, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT03723928

Icon

Phase NA

2

Identifying <span class="highlight">Tumor</span> <span class="highlight">Markers</span> That Predict Treatment Response for Advanced Breast Cancer

Correlation of Molecular <span class="highlight">Markers</span> With Response to Therapy and Breast Cancer Behavior

Purpose: To collect biological specimens and clinical information to identify <span class="highlight">tumor</span> <span class="highlight">markers</span> that predict treatment response.

Who is this for?: People with advanced (stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following at diagnosis, during chemotherapy, and prior to surgery: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Core biopsy</li> <li class="seamTextUnorderedListItem"><span class="highlight">Blood</span> sampling</li> <li class="seamTextUnorderedListItem">Assessment of <span class="highlight">tumor</span> <span class="highlight">markers</span></li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are trying to find ways to determine which tumors will respond to which treatments.</li> <li class="seamTextUnorderedListItem">Studying <span class="highlight">tumor</span> tissue and <span class="highlight">blood</span> samples from patients before and after cancer treatments may help researchers identify <span class="highlight">tumor</span> <span class="highlight">markers</span> that can guide treatment choices.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01000883' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/mbc-pharmacogenomics/' target='_blank'>Metastatic Trial Talk: Why Does The Same Drug Work Differently In Different People?</a> </li></ul>
2

Identifying <span class="highlight">Tumor</span> <span class="highlight">Markers</span> That Predict Treatment Response for Advanced Breast Cancer

Correlation of Molecular <span class="highlight">Markers</span> With Response to Therapy and Breast Cancer Behavior
Icon

Nearest Location:
2406 miles
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, NC

Icon

Visits:
3 visits

Icon

ClinicalTrials.gov: NCT01000883

Icon

Phase NA

HELP GUIDE
HELP GUIDE